Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Liabilities: 2015-2024

Historic Total Liabilities for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to $436.7 million.

  • Syndax Pharmaceuticals' Total Liabilities rose 634.88% to $436.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $436.4 million, marking a year-over-year increase of 634.88%. This contributed to the annual value of $436.7 million for FY2024, which is 644.14% up from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Total Liabilities of $436.7 million as of FY2024, which was up 644.14% from $58.7 million recorded in FY2023.
  • Syndax Pharmaceuticals' Total Liabilities' 5-year high stood at $436.7 million during FY2024, with a 5-year trough of $29.8 million in FY2022.
  • Over the past 3 years, Syndax Pharmaceuticals' median Total Liabilities value was $58.7 million (recorded in 2023), while the average stood at $175.1 million.
  • In the last 5 years, Syndax Pharmaceuticals' Total Liabilities decreased by 27.86% in 2022 and then skyrocketed by 644.14% in 2024.
  • Over the past 5 years, Syndax Pharmaceuticals' Total Liabilities (Yearly) stood at $48.4 million in 2020, then decreased by 14.74% to $41.3 million in 2021, then declined by 27.86% to $29.8 million in 2022, then surged by 97.01% to $58.7 million in 2023, then spiked by 644.14% to $436.7 million in 2024.